Everest Medicines Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Everest Medicines stock has a consensus rating of "Buy" and an average price target of $47.10. The average 1-year stock price forecast is 76.54% higher than the current stock price, while the lowest is $25.58 (-4.12%) and the highest is $69.04 (+158.77%).

Price Target: $47.10 (+76.54%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$25.58	$47.10	$41.60	$69.04
Change	-4.12%	+76.54%	+55.92%	+158.77%

* Price targets were last updated on Apr 18, 2026.

Analyst Ratings

The average analyst rating for Everest Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	3	3	3	3	3	3
Buy	0	0	0	0	0	0
Hold	4	4	4	4	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst BOCOM International Holdings Company No rating	BOCOM International Holdings Company	Buy Maintains $84.00	Buy	Maintains	$84.00	+214.84%	Apr 18, 2026
Unknown Analyst CICC No rating	CICC	Buy Maintains $55.00	Buy	Maintains	$55.00	+106.15%	Apr 5, 2026

Financial Forecast

Revenue This Year

3.30B

from 1.71B

93.43%

from 1.71B

Revenue Next Year

3.96B

from 3.30B

19.99%

from 3.30B

EPS This Year

0.41

from 0.56

-26.30%

from 0.56

EPS Next Year

1.16

from 0.41

182.93%

from 0.41

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	54.00K	12.79M	125.93M	706.68M	1.71B	3.30B
Revenue Growth	-	23,588.89%	884.46%	461.16%	141.51%	93.43%
Gross Profit	31.00K	8.15M	91.52M	524.88M	1.18B	2.41B
Gross Margin	57.41%	63.69%	72.67%	74.27%	69.25%	72.95%
Operating Income	-1.05B	-1.40B	-851.27M	-780.21M	-343.89M	217.34M
Net Income	-1.01B	-247.28M	-844.46M	-1.04B	-297.77M	229.80M
EPS	-	-	-	-	0.56	0.41
EPS Growth	-	-	-	-	-	-26.30%
Forward PE	-	-	-	-	95.03	56.17
Free Cash Flow	-1.34B	-2.03B	2.36B	-689.33M	-228.39M	115.41M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue	2026	2027	2028
High	4.1B
Avg	3.3B
Low	2.8B

Revenue Growth

Revenue Growth	2026	2027	2028
High	140.8%
Avg	93.4%
Low	66.4%

EPS Forecast

EPS	2026	2027	2028
High	0.41
Avg	0.41
Low	0.41

EPS Growth

EPS Growth	2026	2027	2028
High	-26.3%
Avg	-26.3%
Low	-26.3%